Budesonide
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | TARPEYO | — | 2023-12-20 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | ENTOCORT EC | — | 2005-04-29 – 2016-04-29 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | RHINOCORT ALLERGY | — | 2001-10-26 – 2015-03-23 | fda.gov ↗ |
| Approved | EU (EMA) | DuoResp Spiromax | — | 2014-04-28 | europa.eu ↗ |
| Refused (EMA) | EU (EMA) | Labazenit | — | 2013-09-06 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | PULMICORT RESPULES | — | 2003-02-26 – 2005-06-30 | fda.gov ↗ |
| Label expansion | US (FDA) | PULMICORT | — | 1998-10-08 | fda.gov ↗ |
| Approved | US (FDA) | RHINOCORT | — | 1994-02-14 | fda.gov ↗ |
Trials 344 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07081399 | Aug 2024 → Mar 2025 overdue | — | Damanhour University | Recruiting | No outcome recorded |
| Phase 0 | NCT04476628 | Feb 2021 → Jan 2022 | chronic rhinosinusitis | St. Paul's Hospital, Canada | Withdrawn | No outcome recorded |
| Phase 0 | NCT04077892 | Jun → Sep 2016 | allergic rhinitis | Beijing Tongren Hospital | Completed | No outcome recorded |
| Phase 140 trials | ||||||
| Phase 1 | NCT07433569 | Mar → Jun 2026 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT07267130 | Nov 2025 → Oct 2026 expected | chronic obstructive pulmonary disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06723756 | Jan → Jun 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06514157 | Aug → Sep 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06268301 | Feb 2023 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT06367881 | Aug 2022 → Jul 2024 | inflammatory disease, pulmonary immaturity, respiratory distress syndrome in premature infants | Ain Shams University | Unknown | No outcome recorded |
| Phase 1 | NCT05148312 | Nov → Dec 2021 | — | Aquilon Pharmaceuticals S.A. | Completed | No outcome recorded |
| Phase 1 | NCT05519514 | Jul → Aug 2021 | — | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT04848662 | May → Jul 2021 | asthma | Bond Avillion 2 Development LP | Completed | No outcome recorded |
| Phase 1 | NCT04600505 | Oct 2020 → May 2021 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04080713 | Sep 2019 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04016220 | May → Dec 2019 | acute asthma | University of Monastir | Unknown | No outcome recorded |
| Phase 1 | NCT03934333 | May → Sep 2019 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03906045 | Apr 2019 → Mar 2020 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03436225 | Feb 2019 | respiratory syncytial virus bronchiolitis | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT03772223 | Jan → May 2019 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05429775 | Dec 2018 → Jan 2019 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT03740373 | Sep → Oct 2018 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03537326 | May → Jul 2018 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT03421730 | Dec 2017 → Mar 2018 | asthma, reactive airway disease | Vectura Limited | Completed | No outcome recorded |
| Phase 1 | NCT03311373 | Oct → Dec 2017 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03250182 | Aug → Dec 2017 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04032834 | Feb → May 2017 | asthma | Vectura Limited | Completed | No outcome recorded |
| Phase 1 | NCT02811016 | Jun → Jul 2016 | acute mountain sickness | Salzburger Landeskliniken | Completed | No outcome recorded |
| Phase 1 | NCT02631941 | Jan → Jul 2016 | asthma | Zambon SpA | Completed | No outcome recorded |
| Phase 1 | NCT03073057 | Jan → Mar 2016 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02237508 | Sep 2014 → Feb 2015 | asthma | Zambon SpA | Completed | No outcome recorded |
| Phase 1 | NCT02197975 | Aug → Oct 2014 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02187445 | Jun 2014 → Dec 2016 | acute chest syndrome, asthma, sickle cell disease | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT01950507 | Feb 2014 → May 2018 | graft versus host disease | National Institutes of Health Clinical Center (CC) | Terminated | No outcome recorded |
| Phase 1 | NCT02165033 | Nov 2012 → Jan 2013 | asthma | Intech Biopharm Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01511302 | Jun 2012 → Apr 2013 | asthma | Revalesio Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02165046 | Feb → Apr 2012 | asthma, chronic obstructive pulmonary disease | Intech Biopharm Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01423305 | Aug → Oct 2011 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01386996 | Jul → Nov 2011 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01181063 | Aug → Oct 2010 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT00975754 | Sep → Nov 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00569712 | Jan 2007 → Dec 2008 | lung cancer, precancerous condition | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 1 | NCT00627679 | Dec 2005 | asthma | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT00004842 | May 1997 → Apr 1999 | cirrhosis of liver, primary sclerosing cholangitis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT06855043 | Sep 2026 → Mar 2029 expected | respiratory distress syndrome in premature infants | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07270302 | Dec 2025 → May 2026 overdue | chronic rhinosinusitis | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06110403 | Sep 2023 → Sep 2026 expected | chronic obstructive pulmonary disease | University Hospital, Lille | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04964414 | Sep 2021 → Jan 2023 | COVID-19, anosmia, olfactory nerve disorder | Amanda Stapleton | Terminated | No outcome recorded |
| Phase 1/2 | NCT04019106 | Oct 2019 → Oct 2020 | bronchopulmonary dysplasia, respiratory distress syndrome in premature infants | University of Manitoba | Unknown | No outcome recorded |
| Phase 1/2 | NCT03250975 | Aug 2017 → Dec 2026 expected | — | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02907593 | Sep 2016 → Apr 2018 | bronchopulmonary dysplasia | Cynthia McEvoy | Terminated | No outcome recorded |
| Phase 250 trials | ||||||
| Phase 2 | NCT06860542 | Feb 2026 → Dec 2029 expected | pneumonitis | AHS Cancer Control Alberta | Recruiting | No outcome recorded |
| Phase 2 | NCT06830109 | Oct 2024 → Dec 2026 expected | nasal disorder | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06482294 | Jun 2024 → May 2025 | asthma | Università degli Studi di Ferrara | Unknown | No outcome recorded |
| Phase 2 | NCT05915104 | Jan 2024 → Sep 2026 expected | microscopic colitis | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05405387 | May 2023 → Dec 2026 expected | plasma cell leukemia, plasma cell myeloma | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT05055414 | Nov 2021 → Oct 2022 | COVID-19 | Korea United Pharm. Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT04918953 | Jun 2021 → Dec 2025 overdue | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05214599 | Apr 2021 → Nov 2024 | eosinophilic esophagitis | Bazell Pharma AG | Withdrawn | No outcome recorded |
| Phase 2 | NCT04416399 | Jul 2020 → Jan 2021 | COVID-19 | University of Oxford | Terminated | No outcome recorded |
| Phase 2 | NCT03716115 | May 2020 → Apr 2021 | protein-energy malnutrition | Queen Mary University of London | Completed | No outcome recorded |
| Phase 2 | NCT04064684 | Feb → Mar 2020 | pediatric acute respiratory distress syndrome | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| Phase 2 | NCT01895075 | Jan 2019 → Jul 2020 | bronchopulmonary dysplasia | Dr. Michael Dunn | Withdrawn | No outcome recorded |
| Phase 2 | NCT03803787 | Sep 2018 → Dec 2026 expected | radiation pneumonitis | National Cancer Institute of Mexico | Recruiting | No outcome recorded |
| Phase 2 | NCT03304626 | Jun 2017 → Dec 2019 | acute transplant rejection, disease related to solid organ transplantation | University of Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT02991859 | Feb 2017 → Dec 2018 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02991768 | Jan 2017 → Apr 2019 | diarrheal disease | University of Kansas Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT02862509 | Nov 2015 → Aug 2017 | chronic frontal sinusitis | Khon Kaen University | Unknown | No outcome recorded |
| Phase 2 | NCT02550418 | Oct 2015 → Mar 2017 | ulcerative colitis | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02833480 | Feb 2015 → Jan 2021 | chronic obstructive pulmonary disease | University of British Columbia | Unknown | No outcome recorded |
| Phase 2 | NCT02400476 | Feb 2015 → Apr 2021 | HER2 positive breast carcinoma | Puma Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02196077 | Aug 2014 → Mar 2015 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02105012 | Apr 2014 → Sep 2015 | asthma | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02069847 | Feb 2014 → Jan 2019 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01966783 | Sep 2013 → Aug 2015 | proctitis | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01783821 | Jul 2013 → Jul 2015 | adult acute respiratory distress syndrome | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT01814618 | Mar → Nov 2013 | chronic rhinosinusitis, olfactory nerve disorder | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded |
| Phase 2 | NCT02162784 | Feb 2013 → Aug 2014 | asthma | Intech Biopharm Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01738035 | Dec 2012 → Jun 2015 | IgA glomerulonephritis | Calliditas Therapeutics AB | Completed | No outcome recorded |
| Phase 2 | NCT01642212 | Jul 2012 → Oct 2014 | eosinophilic esophagitis | Shire | Completed | No outcome recorded |
| Phase 2 | NCT01858129 | Mar 2012 → May 2015 | persistent tachypnoe of infancy | Bnai Zion Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02280616 | Jun 2011 → Apr 2013 | eosinophilic esophagitis | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01268215 | Jul 2010 → Jun 2012 | bronchopulmonary dysplasia | East Carolina University | Unknown | No outcome recorded |
| Phase 2 | NCT01136382 | Jul 2010 → Apr 2013 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01070524 | Jan → Jul 2010 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT00995904 | Sep → Nov 2009 | asthma | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT00762073 | Jan 2009 → Apr 2010 | eosinophilic esophagitis | Shire | Completed | No outcome recorded |
| Phase 2 | NCT00805285 | Oct 2008 → Oct 2009 | ulcerative colitis | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT00828230 | Sep 2008 → Aug 2011 | radiation proctitis | Dr. Falk Pharma GmbH | Terminated | No outcome recorded |
| Phase 2 | NCT00624754 | Mar 2008 → Jul 2012 | obstructive lung disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT00554970 | Nov 2007 → Jan 2008 | asthma | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT00697801 | Jul → Dec 2006 | asthma | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT00321893 | Jan 2006 → Sep 2008 | lung cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00271349 | Dec 2005 → Jul 2008 | eosinophilic esophagitis | Swiss EE Study Group | Completed | No outcome recorded |
| Phase 2 | NCT00767221 | Oct 2005 → Nov 2008 | IgA glomerulonephritis | Calliditas Therapeutics AB | Completed | No outcome recorded |
| Phase 2 | NCT00117182 | Jul 2005 → Aug 2006 | chronic obstructive pulmonary disease | Syntara | Completed | No outcome recorded |
| Phase 2 | NCT00641693 | Apr 2004 → May 2005 | allergic rhinitis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00658255 | Oct 2002 → May 2003 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00641979 | Apr → Aug 2002 | seasonal allergic rhinitis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00239278 | Jan 2001 → Jan 2005 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00005880 | Jul 2000 → ? | lung cancer | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT06719622 | Jul 2024 → Dec 2027 expected | Crohn disease | Medical University of Warsaw | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT05931744 | May 2021 → Feb 2023 | chronic rhinosinusitis | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 2/3 | NCT04920838 | Apr 2021 → Aug 2023 | COVID-19 | ANRS, Emerging Infectious Diseases | Unknown | No outcome recorded |
| Phase 2/3 | NCT04331470 | Apr 2020 | COVID-19 | Fasa University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03519061 | Aug 2019 | chronic ethmoidal sinusitis | Kaiser Permanente | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01907204 | Jul → Aug 2013 | sinusitis | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| Phase 2/3 | NCT01269437 | Dec 2010 → Oct 2011 | asthma | NovaMed Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT02024659 | Sep 2010 → Dec 2011 | nasal cavity polyp | Beijing Tongren Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00838214 | Mar 2001 → Dec 2008 | autoimmune hepatitis | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT00175747 | Jan 2000 → Dec 2002 | lung cancer | University of British Columbia | Completed | No outcome recorded |
| Phase 3118 trials | ||||||
| Phase 3 | NCT06471257 | Jun 2024 → Oct 2026 expected | asthma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06429475 | Jun 2024 → Dec 2028 expected | asthma | University of KwaZulu | Recruiting | No outcome recorded |
| Phase 3 | NCT06307665 | May 2024 → Oct 2027 expected | asthma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06283966 | Feb 2024 → Dec 2027 expected | chronic obstructive pulmonary disease | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06075095 | Jan 2024 → Aug 2025 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT06245551 | Dec 2023 → Jun 2024 | exercise-induced bronchoconstriction | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT05509933 | Nov 2022 → Dec 2027 expected | engraftment syndrome | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 3 | NCT05555290 | Sep 2022 → Nov 2024 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT05573464 | Sep 2022 → Mar 2024 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT05505734 | Sep 2022 → Aug 2024 | asthma | Bond Avillion 2 Development LP | Completed | No outcome recorded |
| Show all 118 trials opens the full record — a long page | ||||||
| Phase 488 trials | ||||||
| Phase 4 | NCT05976802 | Jun 2027 → Jun 2029 expected | ulcerative colitis | Bausch Health Americas, Inc. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06531798 | Dec 2025 → Oct 2026 expected | chronic obstructive pulmonary disease | AstraZeneca | Recruiting | No outcome recorded |
| Phase 4 | NCT07073950 | Nov 2025 → May 2027 expected | chronic obstructive pulmonary disease | AstraZeneca | Recruiting | No outcome recorded |
| Phase 4 | NCT07166939 | Nov 2025 → Jun 2027 expected | acute asthma | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07030894 | Sep 2025 → Dec 2026 expected | IgA glomerulonephritis, chronic kidney disease, proteinuria | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| Phase 4 | NCT07491991 | Mar 2025 → Jan 2026 | — | Qianfoshan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06676384 | Feb 2025 → Aug 2029 expected | IgA glomerulonephritis, chronic kidney disease, immunoglobulin A vasculitis | Christian Medical College, Vellore, India | Recruiting | No outcome recorded |
| Phase 4 | NCT06785662 | Feb 2025 → Jan 2026 overdue | allergic rhinitis | Siriraj Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06712407 | Dec 2024 → May 2026 overdue | IgA glomerulonephritis | Calliditas Therapeutics AB | Recruiting | No outcome recorded |
| Phase 4 | NCT06590740 | Oct 2024 → Sep 2025 | cough variant asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT06563102 | Sep 2024 → Feb 2026 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT06422689 | May 2024 → Feb 2027 expected | asthma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06841406 | May 2024 → May 2026 overdue | dyspepsia | Universitaire Ziekenhuizen KU Leuven | Recruiting | No outcome recorded |
| Phase 4 | NCT05970263 | Jan 2024 → Dec 2025 | chronic obstructive pulmonary disease | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 4 | NCT06076304 | Nov 2023 → Oct 2028 expected | sinusitis | Daniel Merenstein | Recruiting | No outcome recorded |
| Phase 4 | NCT06571942 | Nov 2023 → Jan 2025 overdue | chronic obstructive pulmonary disease | National Institute of Respiratory Diseases, Mexico | Recruiting | No outcome recorded |
| Phase 4 | NCT04314375 | Sep 2023 → Dec 2026 expected | ulcerative colitis | Bausch Health Americas, Inc. | Recruiting | No outcome recorded |
| Phase 4 | NCT06858423 | Aug 2023 → Mar 2024 | allergic rhinitis | Benha University | Completed | No outcome recorded |
| Phase 4 | NCT05474924 | Aug → Sep 2022 | nasal cavity polyp | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 4 | NCT03141424 | Jun 2022 → Oct 2024 | asthma | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05444543 | Nov 2021 → Oct 2023 | eosinophilic esophagitis | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05084222 | Nov 2021 → Jun 2023 | asthma | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 4 | NCT04527016 | Oct 2021 → Jun 2023 | childhood onset asthma | Children's Hospital of Fudan University | Completed | No outcome recorded |
| Phase 4 | NCT04374474 | Jan → Dec 2021 | olfactory nerve disorder | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded |
| Phase 4 | NCT04159519 | Jul 2020 → Jan 2023 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT04171180 | May → Sep 2020 | cough variant asthma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04355637 | Apr 2020 → Jun 2021 | COVID-19 | Sara Varea | Completed | No outcome recorded |
| Phase 4 | NCT05364385 | Dec 2019 → Feb 2023 | acute lung injury, bronchopulmonary dysplasia | University of Arizona | Unknown | No outcome recorded |
| Phase 4 | NCT04132570 | Oct 2019 → Jan 2020 | rhinitis | Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division | Completed | No outcome recorded |
| Phase 4 | NCT03866538 | Sep 2019 → Oct 2021 | autoimmune enteropathy, celiac disease, collagenous sprue, diarrhea, glucose-stimulated secretory, with common variable immunodeficiency | Mayo Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT05152355 | Apr 2019 → May 2021 | asthma | Intech Biopharm Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03315052 | Jan 2019 → Jan 2021 | acute transplant rejection | Montefiore Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03615742 | Dec 2018 → Dec 2025 overdue | environmental induced asthma, glucocorticoid resistance | University of British Columbia | Recruiting | No outcome recorded |
| Phase 4 | NCT03478696 | Jun 2018 → Mar 2019 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT03563001 | Jun → Sep 2018 | chronic obstructive pulmonary disease | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03551197 | Jun → Sep 2018 | chronic obstructive pulmonary disease | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03521063 | Jan 2018 → Oct 2019 | bronchopulmonary dysplasia, pulmonary immaturity, respiratory distress syndrome in premature infants | Hospital Central "Dr. Ignacio Morones Prieto" | Unknown | No outcome recorded |
| Phase 4 | NCT03219866 | Oct 2017 → Apr 2020 | chronic obstructive pulmonary disease | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 4 | NCT03369847 | Sep 2017 → May 2019 | asthma, childhood acute lymphoblastic leukemia | New York City Health and Hospitals Corporation | Completed | No outcome recorded |
| Phase 4 | NCT03034005 | Mar 2017 → Feb 2019 | asthma | Bispebjerg Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03394222 | Jul 2016 → Mar 2017 | lung cancer | Fujian Medical University Union Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02771717 | May 2016 → Jul 2017 | asthma | University of Nottingham | Unknown | No outcome recorded |
| Phase 4 | NCT02696850 | Jan 2016 → Apr 2017 | chronic rhinosinusitis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03028701 | Sep 2015 → Mar 2017 | chronic obstructive pulmonary disease | Neutec Ar-Ge San ve Tic A.Ş | Completed | No outcome recorded |
| Phase 4 | NCT02934945 | Sep 2015 → Jan 2017 | asthma | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02574975 | Apr 2015 → May 2016 | asthma | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02357277 | Mar 2015 → Nov 2017 | osteoporosis | Columbia University | Withdrawn | No outcome recorded |
| Phase 4 | NCT04520230 | Oct 2014 → Dec 2019 | chronic obstructive pulmonary disease | Tanta University | Completed | No outcome recorded |
| Phase 4 | NCT02055352 | May 2014 → Jan 2016 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02409563 | Jan → Mar 2014 | allergic rhinitis | Istituto per la Ricerca e l'Innovazione Biomedica | Completed | No outcome recorded |
| Phase 4 | NCT01794780 | Feb 2013 → May 2015 | chronic obstructive pulmonary disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01846962 | Nov 2012 → Apr 2013 | eosinophilic esophagitis | Azienda Policlinico Umberto I | Completed | No outcome recorded |
| Phase 4 | NCT01253473 | Apr 2012 → Sep 2015 | chronic obstructive pulmonary disease | National Jewish Health | Completed | No outcome recorded |
| Phase 4 | NCT01520688 | Feb 2012 → Feb 2016 | asthma | West Penn Allegheny Health System | Completed | No outcome recorded |
| Phase 4 | NCT01760304 | Jan → Jul 2012 | chronic obstructive pulmonary disease | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01397890 | Jul 2011 → Jun 2013 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01329276 | Jun → Nov 2010 | chronic obstructive pulmonary disease | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 4 | NCT00997477 | Jun → Jul 2010 | asthma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT01340118 | May → Jul 2010 | asthma | Chungbuk National University | Completed | No outcome recorded |
| Phase 4 | NCT01070888 | Feb 2010 → Apr 2014 | exercise-induced bronchoconstriction | Boston Children's Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00939341 | Jul 2009 → Aug 2010 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00883532 | Apr 2009 → Dec 2012 | bronchopulmonary dysplasia, respiratory distress syndrome in premature infants | China Medical University, China | Unknown | No outcome recorded |
| Phase 4 | NCT00661973 | Apr 2008 → Dec 2010 | asthma | Imperial College London | Withdrawn | No outcome recorded |
| Phase 4 | NCT00624429 | Mar 2008 → Dec 2009 | asthma | Phoenix Children's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01225913 | Oct 2007 → Jun 2027 expected | asthma | Gelb, Arthur F., M.D. | Recruiting | No outcome recorded |
| Phase 4 | NCT01186653 | Oct 2007 → May 2010 | chronic obstructive pulmonary disease | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT00584636 | Oct 2007 → Mar 2009 | asthma | Phoenix Children's Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT00489853 | Jul 2007 → Aug 2008 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00397267 | Jan → Dec 2007 | acute asthma | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00393367 | Dec 2006 → Nov 2007 | acute asthma, reactive airway disease | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 4 | NCT00395239 | Oct 2006 → Oct 2015 | asthma | University of Alberta | Terminated | No outcome recorded |
| Phase 4 | NCT00380484 | Sep 2006 → Feb 2008 | asthma | Children´s Clinic, Randers | Completed | No outcome recorded |
| Phase 4 | NCT00379028 | Sep 2006 → Jul 2007 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00338910 | May → Jun 2006 | — | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 4 | NCT01089322 | Dec 2005 → Apr 2009 | asthma | Rafael Stelmach | Completed | No outcome recorded |
| Phase 4 | NCT00202189 | Sep → Nov 2005 | chronic obstructive pulmonary disease | Queen's University | Completed | No outcome recorded |
| Phase 4 | NCT00228475 | Sep 2004 → Oct 2005 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00146497 | Aug 2004 → ? | pulmonary immaturity, respiratory distress syndrome in premature infants | China Medical University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00560586 | Apr 2004 → May 2006 | obstructive sleep apnea syndrome | University of Louisville | Completed | No outcome recorded |
| Phase 4 | NCT00272753 | Apr 2004 → Nov 2005 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00490243 | Jul 2003 → Oct 2006 | asthma | Medical University of Lodz | Completed | No outcome recorded |
| Phase 4 | NCT00479739 | Nov 2002 → Jul 2004 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00641472 | Oct 2002 → Feb 2005 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00641446 | Oct 2001 → Oct 2003 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00641212 | Jan 2000 → Apr 2003 | perennial allergic rhinitis | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00232674 | Jul 1999 → Feb 2004 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00234390 | Nov 1998 → Dec 2004 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00641914 | Oct 1996 → Feb 2003 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable28 trials | ||||||
| — | NCT07528820 | Jul 2026 overdue | chronic rhinosinusitis | St. Paul's Sinus Centre | Not yet recruiting | No outcome recorded |
| — | NCT07595796 | Jun 2026 → Feb 2028 expected | — | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT07560462 | May 2026 → May 2029 expected | — | Shaare Zedek Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT07386860 | Mar 2026 → Dec 2028 expected | olfactory nerve disorder | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06890260 | Apr 2025 → Jun 2027 expected | allergic rhinitis | Pengfei Qiu | Recruiting | No outcome recorded |
| — | NCT06597682 | Mar 2025 → Jul 2027 expected | long COVID-19 | Huashan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06105671 | Jan → Jul 2024 | — | Morten Hostrup, PhD | Completed | No outcome recorded |
| — | NCT04675463 | Dec 2020 → Jan 2023 | chronic obstructive pulmonary disease | ShiYue Li | Unknown | No outcome recorded |
| — | NCT04002349 | Jul → Dec 2019 | — | Beijing Tongren Hospital | Unknown | No outcome recorded |
| — | NCT05541419 | Aug 2018 → Aug 2022 | chronic rhinosinusitis | State University of Londrina | Unknown | No outcome recorded |
| — | NCT03504527 | May → Nov 2018 | bronchial disorder | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT02562924 | Nov 2015 → Dec 2017 | chronic rhinosinusitis | University of Vermont Medical Center | Completed | No outcome recorded |
| — | NCT02013115 | Jan 2015 → Oct 2017 | newborn respiratory distress syndrome | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| — | NCT01457716 | Oct → Nov 2011 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| — | NCT01526707 | Jun 2011 → Aug 2014 | asthma | Liam Heaney | Completed | No outcome recorded |
| — | NCT01373528 | Dec 2010 → May 2012 | chronic rhinosinusitis | Ottawa Hospital Research Institute | Terminated | No outcome recorded |
| — | NCT00961233 | Oct 2009 → Aug 2011 | eosinophilic esophagitis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT00859274 | Mar 2009 → Oct 2013 | asthma | Kuopio University Hospital | Completed | No outcome recorded |
| — | NCT01055041 | Dec 2008 → Jun 2009 | chronic asthma | Government Medical College, Bhavnagar | Completed | No outcome recorded |
| — | NCT01219036 | Oct 2008 → Jul 2011 | asthma | Liam Heaney | Completed | No outcome recorded |
| — | NCT01219738 | Jul 2008 → Aug 2012 | asthma | University of Miami | Completed | No outcome recorded |
| — | NCT00587119 | Dec 2007 → Jul 2009 | autoimmune hepatitis, primary biliary cholangitis | Mayo Clinic | Withdrawn | No outcome recorded |
| — | NCT00388739 | Nov 2006 | asthma | Baylor College of Medicine | Withdrawn | No outcome recorded |
| — | NCT00159263 | Nov 2004 → Nov 2006 | asthma | Imperial College London | Completed | No outcome recorded |
| — | NCT01378039 | Jun 2004 → Dec 2006 | asthma, chronic obstructive pulmonary disease | Lithuanian University of Health Sciences | Completed | No outcome recorded |
| — | NCT00728715 | Jan 2004 → Jan 2005 | bronchiectasis | Hospital General de Requena | Completed | No outcome recorded |
| — | NCT00184171 | Nov 2001 → Sep 2010 | microscopic colitis | Norwegian University of Science and Technology | Terminated | No outcome recorded |
| — | NCT00135681 | Dec 1996 → Nov 2001 | asthma, lung disorder | University of New Mexico | Completed | No outcome recorded |
Also used as a comparator or background therapy in 172 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07358234 Comparator | Feb 2026 → Dec 2027 expected | eosinophilic esophagitis | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT04267042 Comparator | Feb 2020 → Feb 2021 | chronic rhinosinusitis, fungal infectious disease | St. Paul's Hospital, Canada | Unknown | No outcome recorded |
| Phase 0 | NCT04097613 Background | Jul 2017 → Apr 2019 | chronic rhinosinusitis | St. Paul's Hospital, Canada | Completed | No outcome recorded |
| Phase 0 | NCT01257048 Comparator | Aug 2011 → Jun 2012 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06297668 Comparator | Apr → Jun 2024 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02934607 Comparator | Nov 2016 → Mar 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01849406 Comparator | Apr → Sep 2013 | — | Ioannis Koutsourelakis | Completed | No outcome recorded |
| Phase 1 | NCT00595153 Comparator | Apr 2007 → Jun 2011 | asthma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06657079 Comparator | May 2024 → Jan 2025 | acute respiratory distress syndrome | Damanhour University | Completed | No outcome recorded |
| Phase 1/2 | NCT05689983 Comparator | Apr 2022 → Dec 2025 overdue | childhood onset asthma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03319043 Background | Nov 2017 → Dec 2018 | cough variant asthma | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT01955980 Comparator | Oct 2015 → Sep 2018 | chronic rhinosinusitis | Pari Pharma GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT01946711 Comparator | Aug 2013 → Feb 2020 | chronic rhinosinusitis, polyposis | Pari Pharma GmbH | Completed | No outcome recorded |
| Phase 228 trials | ||||||
| Phase 2 | NCT07499791 Comparator | May 2026 → Dec 2027 expected | chronic dacryocystitis | Beijing Tongren Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06940700 Comparator | Apr → Oct 2025 overdue | asthma | Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06676319 Background | Nov 2024 → Jun 2027 expected | asthma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05269030 Comparator | Jul 2022 → Mar 2023 | — | Menoufia University | Unknown | No outcome recorded |
| Phase 2 | NCT05269017 Comparator | Jun 2022 → Mar 2023 | — | Menoufia University | Unknown | No outcome recorded |
| Phase 2 | NCT04589663 Background | Jun 2021 → Apr 2022 | asthma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04422275 Comparator | Jun 2021 → Jun 2023 | anosmia | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT04294641 Background | May 2021 → Jun 2024 | chronic graft versus host disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT04163978 Comparator | Oct 2019 → May 2022 | chronic rhinosinusitis | Sanotize Research and Development corp. | Completed | No outcome recorded |
| Phase 2 | NCT02986321 Comparator | Dec 2016 → Oct 2017 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT02573233 Background | Jan 2016 → Jan 2018 | asthma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT02425813 Background | Oct 2015 → Jul 2016 | acute graft versus host disease | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2 | NCT01783106 Comparator | Feb 2014 → Apr 2019 | Crohn disease | Royal Liverpool University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01821898 Comparator | Jul 2013 → Sep 2018 | eosinophilic esophagitis | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT01555099 Comparator | Apr 2012 → Apr 2013 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01225549 Comparator | Nov 2010 → Dec 2011 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01136655 Background | Sep 2010 → Dec 2011 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01200108 Comparator | Mar 2010 → Oct 2011 | asthma | Activaero GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00989833 Comparator | Sep 2009 → Jul 2010 | exercise-induced bronchoconstriction | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01293734 Comparator | Dec 2008 → Jan 2011 | acute asthma | Liaoning University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00940953 Comparator | Feb → May 2008 | seasonal allergic rhinitis | Ligand Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00634413 Background | Feb → Dec 2008 | chronic obstructive pulmonary disease | Pulmagen Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00638456 Comparator | Feb 2008 → Sep 2009 | eosinophilic esophagitis | Ranjan Dohil | Completed | No outcome recorded |
| Phase 2 | NCT00483743 Comparator | Nov 2007 → Dec 2008 | chronic obstructive pulmonary disease | Syntara | Completed | No outcome recorded |
| Phase 2 | NCT00938613 Comparator | Feb → Apr 2007 | seasonal allergic rhinitis | Ligand Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00327808 Comparator | May 2006 → Mar 2007 | asthma | Syntara | Completed | No outcome recorded |
| Phase 2 | NCT00135408 Comparator | Dec 2005 → Jul 2007 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00109473 Comparator | Apr 2005 → Jul 2009 | Crohn disease | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT04027322 Comparator | Jun 2019 → May 2022 | acute pharyngitis | Oman Medical Speciality Board | Completed | No outcome recorded |
| Phase 2/3 | NCT01857479 Background | May 2013 → Jun 2015 | allergic bronchopulmonary aspergillosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT01524198 Comparator | Nov 2010 → Apr 2012 | status asthmaticus | King Saud University | Completed | No outcome recorded |
| Phase 2/3 | NCT00728481 Comparator | May 2008 → Dec 2010 | eosinophilic esophagitis, gastroesophageal reflux disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT00633919 Comparator | Jul 2006 → Dec 2008 | allergic disease | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 2/3 | NCT00217022 Comparator | Jun 2003 → Feb 2008 | diarrheal disease, lymphocytic colitis | Mayo Clinic | Terminated | No outcome recorded |
| Phase 352 trials | ||||||
| Phase 3 | NCT07318350 Comparator | Oct 2026 → Mar 2028 expected | — | Eurofarma Laboratorios S.A. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05735431 Comparator | Jun 2026 → Nov 2027 | chronic asthma | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT07383402 Comparator | Mar 2026 → Dec 2027 expected | chronic rhinosinusitis | Amin Javer | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06502366 Comparator | Jul 2024 → Mar 2026 overdue | asthma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06067828 Comparator | Oct 2023 → Jan 2026 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT05878093 Background | May 2023 → Sep 2024 | chronic rhinosinusitis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT05562466 Comparator | May 2023 → Feb 2028 expected | asthma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT04233190 Comparator | Apr 2023 → Oct 2024 | asthma | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT05755906 Comparator | Feb 2023 → Nov 2024 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04191447 Comparator | Jul 2022 → Jul 2023 | asthma | EMS | Unknown | No outcome recorded |
| Phase 3 | NCT04727424 Comparator | Jan 2021 → Jun 2024 | COVID-19 | Cardresearch | Unknown | No outcome recorded |
| Phase 3 | NCT04609878 Background | Dec 2020 → Mar 2025 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04193878 Comparator | Jun 2020 → Jul 2025 | acute respiratory failure, pneumonia | Stanford University | Terminated | No outcome recorded |
| Phase 3 | NCT04215848 Comparator | Apr 2020 → Oct 2021 | asthma | Hat Yai Medical Education Center | Completed | No outcome recorded |
| Phase 3 | NCT04208581 Background | Oct 2019 → Dec 2021 | chronic obstructive pulmonary disease, respiratory failure | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03847896 Comparator | Mar 2019 → Jul 2021 | asthma | Bond Avillion 2 Development LP | Completed | No outcome recorded |
| Phase 3 | NCT03755557 Comparator | Nov 2018 → Apr 2019 | conjunctivitis, seasonal allergic rhinitis | Marinomed Biotech AG | Completed | No outcome recorded |
| Phase 3 | NCT03888131 Comparator | Jul 2018 → May 2022 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT03081247 Background | Apr → Dec 2018 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT03197818 Comparator | Dec 2016 → May 2020 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT02668861 Background | May 2016 → May 2017 | chronic rhinosinusitis | The First Affiliated Hospital of Shanxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT02497001 Comparator | Aug 2015 → Jan 2018 | chronic obstructive pulmonary disease | Pearl Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02446418 Comparator | Jul 2015 → Jul 2017 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02455687 Comparator | Jun 2015 → Dec 2024 | asthma | Hamad Medical Corporation | Unknown | No outcome recorded |
| Phase 3 | NCT03687515 Comparator | Jan 2015 → Dec 2016 | chronic rhinosinusitis | Beijing Tongren Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02224157 Comparator | Nov 2014 → Aug 2017 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02149199 Comparator | Jul 2014 → Aug 2017 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02157935 Comparator | Jun 2014 → Feb 2016 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01803555 Comparator | Jul 2013 → Mar 2014 | asthma | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01687283 Comparator | Sep 2012 → Nov 2013 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01202084 Comparator | Jan → Nov 2012 | asthma | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01444430 Comparator | Dec 2011 → Oct 2015 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01360021 Comparator | Nov 2011 → Aug 2012 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01351792 Comparator | Sep 2011 → Nov 2012 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded |
| Phase 3 | NCT01602523 Comparator | Mar 2011 → Apr 2014 | pulmonary emphysema | Temple University | Unknown | No outcome recorded |
| Phase 3 | NCT01266772 Comparator | Jan 2011 → Dec 2013 | asthma | Medical University of Lodz | Unknown | No outcome recorded |
| Phase 3 | NCT01089647 Comparator | Sep 2010 → Jun 2014 | obstructive sleep apnea syndrome | Romaker & Associates | Completed | No outcome recorded |
| Phase 3 | NCT01001364 Comparator | Feb 2010 → Apr 2011 | asthma | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01086553 Comparator | Nov 2009 → May 2012 | Crohn disease | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00849095 Comparator | Apr 2009 → Apr 2013 | asthma | Università degli Studi di Ferrara | Completed | No outcome recorded |
| Phase 3 | NCT00826163 Comparator | Jan → Nov 2009 | chronic obstructive pulmonary disease | Mahidol University | Completed | No outcome recorded |
| Phase 3 | NCT00667992 Comparator | Apr 2008 → May 2009 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00536731 Comparator | Sep 2007 → Apr 2008 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00442117 Comparator | Jun 2007 → Jul 2009 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00462592 Comparator | Mar 2007 → Jun 2009 | asthma | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00419757 Comparator | Jan 2007 → Jun 2008 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00413387 Comparator | Sep 2004 → Aug 2005 | asthma | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00651768 Comparator | Aug 2003 → Jan 2005 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00646529 Comparator | Jul 2002 → Oct 2003 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00652002 Comparator | Jul 2002 → Jan 2004 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00651547 Comparator | Jul 2002 → Oct 2003 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00000575 Comparator | Sep 1991 → Oct 1999 | asthma, lung disorder | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 442 trials | ||||||
| Phase 4 | NCT07675252 Comparator | Aug 2026 → May 2027 expected | — | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07052942 Comparator | Aug 2025 → Nov 2029 expected | acute asthma | DARTNet Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06334575 Comparator | Feb 2025 → Dec 2027 expected | chronic obstructive pulmonary disease | Maria Joyera Rodríguez | Recruiting | No outcome recorded |
| Phase 4 | NCT06158893 Comparator | Aug 2024 → Aug 2025 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT06528015 Background | Jul 2024 → Dec 2026 expected | IgA glomerulonephritis | Gang Xu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06272370 Comparator | Feb → Sep 2024 | asthma, hypersensitivity reaction disease, obstructive lung disease, respiratory tract infectious disorder | DARTNet Institute | Completed | No outcome recorded |
| Phase 4 | NCT06209047 Background | Oct 2023 → May 2026 overdue | bronchiectasis | Assiut University | Recruiting | No outcome recorded |
| Phase 4 | NCT05596721 Background | Jan 2023 → Mar 2024 | asthma, lung disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05318157 Background | Mar 2022 → Oct 2024 | allergic rhinitis | Beijing Tongren Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04342039 Comparator | Jan 2021 → Dec 2025 overdue | — | University of British Columbia | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03952286 Background | Aug 2019 → Dec 2020 | childhood onset asthma | University of Arizona | Completed | No outcome recorded |
| Phase 4 | NCT03275415 Comparator | Jul 2019 → Jun 2022 | bronchopulmonary dysplasia, newborn respiratory distress syndrome | Taipei Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03788395 Comparator | Jan 2019 → Jan 2020 | asthma | Istituto per la Ricerca e l'Innovazione Biomedica | Completed | No outcome recorded |
| Phase 4 | NCT02972476 Comparator | Dec 2016 → Jul 2019 | chronic obstructive pulmonary disease | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT02533505 Comparator | Aug 2015 → Aug 2016 | chronic obstructive pulmonary disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02504801 Comparator | Jul 2015 → Jul 2016 | chronic obstructive pulmonary disease, lung neoplasm | Xiuyi Zhi | Unknown | No outcome recorded |
| Phase 4 | NCT02526758 Comparator | Apr 2015 → May 2016 | chronic obstructive pulmonary disease | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02019758 Comparator | Jan 2015 → May 2018 | eosinophilic esophagitis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT02233803 Background | Nov 2014 → Dec 2015 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02257372 Background | Sep 2014 → Mar 2015 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT01912872 Background | Nov 2013 → Aug 2015 | allergic asthma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT01787097 Comparator | Jan 2013 → Dec 2014 | chronic obstructive pulmonary disease | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT01865500 Comparator | Jan → May 2013 | chronic obstructive pulmonary disease | Ataturk University | Completed | No outcome recorded |
| Phase 4 | NCT01712854 Comparator | Mar → Sep 2012 | chronic obstructive pulmonary disease | Columbia University | Terminated | No outcome recorded |
| Phase 4 | NCT01404013 Comparator | Feb 2012 → Aug 2014 | asthma | The First Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01270256 Comparator | Jan 2011 → Jul 2012 | perennial allergic rhinitis | University of Chicago | Completed | No outcome recorded |
| Phase 4 | NCT01147510 Comparator | Jul 2010 → Sep 2012 | chronic asthma | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00912171 Comparator | Jan 2009 → Apr 2010 | obstructive sleep apnea syndrome | University of Bologna | Completed | No outcome recorded |
| Phase 4 | NCT00867737 Comparator | Sep 2008 → Sep 2009 | asthma | Allergy and Asthma Center of El Paso | Unknown | No outcome recorded |
| Phase 4 | NCT00716963 Comparator | Jul → Nov 2008 | intermittent asthma | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00702325 Comparator | Jun 2008 → Sep 2009 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02002715 Comparator | Mar 2008 → May 2018 | chronic bronchitis | The First Affiliated Hospital of Guangzhou Medical University | Completed | No outcome recorded |
| Phase 4 | NCT00733317 Comparator | Sep 2007 → Dec 2009 | acute asthma | Kecioren Education and Training Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00487773 Comparator | Sep 2007 → Sep 2008 | asthma | Medical University of Lodz | Completed | No outcome recorded |
| Phase 4 | NCT00733473 Comparator | Sep 2007 → Dec 2009 | acute asthma | Kecioren Education and Training Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00522782 Comparator | Aug 2007 → Dec 2008 | asthma | AAADRS Clinical Research Center | Completed | No outcome recorded |
| Phase 4 | NCT00860938 Comparator | Apr 2007 → Aug 2010 | chronic obstructive pulmonary disease | Cantonal Hosptal, Baselland | Completed | No outcome recorded |
| Phase 4 | NCT00996697 Comparator | Oct 2006 → Sep 2008 | chronic obstructive pulmonary disease | Brian J Lipworth | Completed | No outcome recorded |
| Phase 4 | NCT00471809 Background | Mar 2006 → Mar 2007 | asthma | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
| Phase 4 | NCT00189436 Comparator | Mar 2003 → Jan 2009 | asthma | Deborah Gentile | Completed | No outcome recorded |
| Phase 4 | NCT00092092 Comparator | Oct 2002 → Jun 2004 | asthma | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00554710 Comparator | May 2001 → Jan 2004 | Crohn disease | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Completed | No outcome recorded |
| Phase not applicable31 trials | ||||||
| — | NCT07329946 Background | Sep 2026 → Feb 2027 expected | chronic obstructive pulmonary disease | Pierachille Santus, MD, PhD | Not yet recruiting | No outcome recorded |
| — | NCT06837051 Comparator | Mar 2025 → Mar 2027 expected | chronic rhinosinusitis, olfactory nerve disorder | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06870292 Comparator | Mar → Dec 2025 overdue | rhinitis | Xu Yu | Recruiting | No outcome recorded |
| — | NCT06756243 Background | Mar → Dec 2025 overdue | allergic rhinitis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| — | NCT07058259 Background | Nov 2024 → Jun 2025 overdue | chronic obstructive pulmonary disease | Istanbul Medeniyet University | Active not recruiting | No outcome recorded |
| — | NCT05791487 Background | Dec 2023 → Mar 2026 overdue | ulcerative colitis | Wolfson Medical Center | Recruiting | No outcome recorded |
| — | NCT05839756 Comparator | May 2023 → Feb 2028 expected | laryngeal disorder | Mansoura University | Recruiting | No outcome recorded |
| — | NCT04952389 Background | Dec 2021 → Apr 2023 | COVID-19, olfactory nerve disorder | Mayo Clinic | Completed | No outcome recorded |
| — | NCT06189586 Comparator | Oct 2021 → Dec 2024 | chronic obstructive pulmonary disease | Dong Yang | Unknown | No outcome recorded |
| — | NCT05904002 Background | Sep 2020 → Sep 2021 | asthma, pregnancy disorder | Cairo University | Completed | No outcome recorded |
| — | NCT03999008 Comparator | Jun 2020 → Jun 2022 | esophageal atresia | St. Justine's Hospital | Unknown | No outcome recorded |
| — | NCT04291118 Background | Feb 2020 → Sep 2021 | chronic rhinosinusitis | St. Paul's Hospital, Canada | Unknown | No outcome recorded |
| — | NCT04561687 Comparator | Jan 2020 → Sep 2021 | allergic rhinitis | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT04233463 Comparator | Jan 2020 → Jan 2021 | Crohn disease | Hillel Yaffe Medical Center | Unknown | No outcome recorded |
| — | NCT02509299 Background | Sep → Nov 2019 | chronic obstructive pulmonary disease | University of Granada | Completed | No outcome recorded |
| — | NCT02790047 Background | Oct 2016 → Jan 2018 | chronic obstructive pulmonary disease | Khon Kaen University | Unknown | No outcome recorded |
| — | NCT02715167 Comparator | Mar → Apr 2016 | — | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Unknown | No outcome recorded |
| — | NCT02515318 Comparator | Sep 2015 → Mar 2017 | chronic obstructive pulmonary disease | University of Granada | Unknown | No outcome recorded |
| — | NCT02194062 Comparator | Jan → Jul 2015 | chronic rhinosinusitis, nasal cavity polyp | Yale University | Completed | No outcome recorded |
| — | NCT02352168 Comparator | Sep 2014 → Oct 2015 | allergic rhinitis | Guangzhou Institute of Respiratory Disease | Completed | No outcome recorded |
| — | NCT02056379 Comparator | Mar 2014 → Mar 2015 | — | Hospital Israelita Albert Einstein | Unknown | No outcome recorded |
| — | NCT01973751 Comparator | Nov 2013 → Jul 2016 | asthma | Tongji Hospital | Unknown | No outcome recorded |
| — | NCT01854515 Comparator | Mar 2012 → Sep 2014 | — | Saeed Abbasi | Unknown | No outcome recorded |
| — | NCT01484691 Comparator | Jan 2012 → Jul 2015 | asthma | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT02257463 Comparator | Oct 2011 → Apr 2014 | chronic obstructive pulmonary disease | Mansoura University | Completed | No outcome recorded |
| — | NCT01786070 Comparator | Mar 2011 → Mar 2014 | — | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01179152 Comparator | Sep 2010 → Oct 2011 | acute asthma | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT01117116 Comparator | Mar 2010 → Sep 2013 | asthma | National Jewish Health | Completed | No outcome recorded |
| — | NCT00706446 Background | Jun 2008 → Jun 2010 | asthma | Brigham and Women's Hospital | Terminated | No outcome recorded |
| — | NCT02318043 Comparator | Jan → Dec 2007 | asthma | Guangzhou Institute of Respiratory Disease | Completed | No outcome recorded |
| — | NCT00319488 Comparator | Feb 2004 → Nov 2006 | asthma, lung disorder | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Press releases naming this drug 8 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-02-12 | Takeda | FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) takeda.com ↗ |
| 2023-09-20 | Takeda | Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE) takeda.com ↗ |
| 2020-12-15 | Takeda | U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis takeda.com ↗ |
| 2016-03-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Completes Generic Pulmicort® Respules Portfolio with the Launch of Third Strength in the United States tevapharm.com ↗ |
| 2010-05-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Reaches Settlement Agreement With AstraZeneca Regarding Generic Entocort® EC Capsules tevapharm.com ↗ |
| 2008-11-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Agreement on Generic Pulmicort Respules® Patent Challenge tevapharm.com ↗ |
| 2008-11-20 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Update on Generic Pulmicort Repulses® Launch tevapharm.com ↗ |
| 2008-11-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Receives First U.S. Approval for Generic Pulmicort Respules®; Commences Commercial Launch tevapharm.com ↗ |
Evidence & citations 56 cited values
Every value below carries the sentence it was read from. 540 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | budesonide | “participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid...” NCT06272370 ↗502“The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA...” NCT06712407 ↗ “compared to the FDC of formoterol 6 mcg/budesonide 200 mcg (Alenia® - Aché Laboratórios Farmacêuticos S.A.) in the maintenance treatment of asthma, allowing its registration as...” NCT05735431 ↗ “BGF 160 (Breztri Aerosphere™ in USA, Trixeo™ in France) Inhalation aerosol: pressurized metered dose inhaler containing a combination of budesonide (160 mcg), glycopyrrolate (9...” NCT06110403 ↗ “160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25...” NCT02631941 ↗ “160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25...” NCT02237508 ↗ “Oral antihistamines (Loratadine) or nasal antihistamines (Azelastine Hydrochloride) are preferred, and nasal hormones (Budesonide nasal spray), or a combination of two or three...” NCT06870292 ↗ “Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized,...” PMID 32253054 ↗ Apr 2020 “Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle...” NCT04374474 ↗ “This study will be conducted to establish the relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with and...” NCT02934607 ↗ “FDA approval of Airsupra (with both albuterol and budesonide in one inhaler) provides a unique opportunity to introduce ICS (along with albuterol) to ED patients with acute asthma.” NCT07166939 ↗ “Triple Therapy (LABA + LAMA + ICS): Patients receive the above combination of LABA and LAMA plus an inhaled corticosteroid (ICS) such as Budesonide, Fluticasone, or Beclometasone.” NCT07058259 ↗ “Infants born at >34 weeks gestational age with TTN at 4 h of age were randomized to two doses, 12 h apart, of inhaled Budesonide 1000 μg/dose or placebo within 6 h from delivery.” PMID 28672098 ↗ Jul 2017 “Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.” NCT02509299 ↗ “The active comparator arm involved 373 patients treated with Symbicort® Turbohaler®, a fixed-dose combination of budesonide (160 µg) and formoterol fumarate (4.5 µg).” NCT03888131 ↗ “Participants will receive Budesonide and Albuterol Sulfate MDI 80/90 μg per Actuation 1 to 6 doses (2 inhalations/dose) per day as needed via Oral inhalation route.” NCT05505734 ↗ “To evaluate the efficacy of 2 formoterol doses added to budesonide as fixed combinations vs budesonide alone in children 6 to younger than 12 years with asthma.” PMID 28256307 ↗ Mar 2017 “Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.” PMID 28363480 ↗ Mar 2017 “Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.” NCT04159519 ↗ “Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).” NCT01351792 ↗ “inhaled dual therapy with budesonide/formoterol fumarate dihydrate with an MDI with a spacer versus a DPI in patients with COPD and low PIF” PMID 35815354 ↗ Jan 2022 “Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide” NCT02515318 ↗ “budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days” NCT01225913 ↗ “When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.” NCT05555290 ↗ “All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation.” NCT03319043 ↗ “a fixed high-dose combination of the inhaled corticosteroid budesonide and the long-acting β(2)-adrenoceptor agonist formoterol” PMID 22024920 ↗ Jan 2012 “Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID” NCT02727660 ↗ “2 mg budesonide suspension for inhalation, nebulized inhalation for minutes,administered 4 times a day for 5 consecutive days.” NCT06189586 ↗ “PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.” NCT02197975 ↗ “Asthmatic patients were randomised to double blind treatment with either placebo or budesonide (800 μg daily for 3 months)” PMID 21939520 ↗ Sep 2011 “The total daily budesonide dose will be 40 μg per subject for Budesolv 10 and 256 μg per subject for Rhinocort® aqua 64.” NCT03755557 ↗ “A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)” NCT03934333 ↗ “a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice” NCT07052942 ↗ “Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)” NCT04589663 ↗ “Budesonide/Glycoperronium/formoterol fumarate pressurised inhalation suspension 160/7.2/4.8 μg per actuation” NCT06297668 ↗ “Budesonide/Arformoterol dry powder inhaler, 3 inhalations b.i.d at 3 days and 2 inhalations b.i.d at 11 days” NCT05055414 ↗ “Budesonide / Formoterol Powder for Inhalation will be used twice daily (320ug/4.5ug each time) for 52 weeks” NCT04208581 ↗ “The combination of formoterol and budesonide (Symbicort ®, Astra Zeneca) will be studied in this project.” NCT01787097 ↗ “fixed-dose combination of budesonide/glycopyrrolate/formoterol fumarate (BGF) 160/9/4.8 μg per actuation” PMID 37607661 ↗ Aug 2023 “Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children.” PMID 28420280 ↗ Apr 2017 “Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)” NCT02196077 ↗ “320 μg of budesonide and 9 μg of formoterol are administered from Bufomix Easyhaler as two inhalations.” NCT05084222 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler” NCT02497001 ↗ “84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol” NCT00995904 ↗ “Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.” NCT03788395 ↗ “Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID” NCT02766608 ↗ “receive formoterol 12mcg / budesonide 400mcg Eurofarma or Alenia® 12mcg / 400mcg during 12 weeks” NCT04233190 ↗ “formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg” NCT01089322 ↗ “Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time” NCT04675463 ↗ “0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks” NCT00569192 ↗ “0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks” NCT00697697 ↗ “Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses” NCT02157935 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010” NCT03262012 ↗ “Budesonide, glycopyrronium, and formoterol fumarate pressurized inhalation suspension” NCT06283966 ↗ “Budesonide/glycopyrronium/formoterol fumarate pressurized inhalation suspension, HFO” NCT06723756 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)” NCT03081247 ↗ “inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)” NCT03504527 ↗ “Five drops of budesonide suspension (2ml:1mg) will be instilled into each nostril” NCT07386860 ↗ “Budesonide and Formoterol Fum arate Powder for Inhalation, 1 inhale, bid for 12w” NCT05596721 ↗ “Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.” NCT00395239 ↗ “PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol.” NCT03250182 ↗ “Budesonide 160 mcg/Glycopyrrolate 7.2 mcg/Formoterol fumarate dehydrate 5 mcg” NCT06531798 ↗ “Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 320/9.6 μg” NCT05202262 ↗ “2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents” NCT00697801 ↗ “Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler” NCT04609904 ↗ “budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler” NCT04609878 ↗ “Symbicort® (Budesonide/Formoterol) Breath Actuated Metered Dose Inhaler” NCT01360021 ↗ “Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks” NCT01404013 ↗ “Participants are administered 54 μg Formoterol and 1920 μg Budesonide” NCT06105671 ↗ “2. 360 ug of budesonide inhalation powder once-daily for at-home use” NCT03952286 ↗ “3 inhalation of Budesonide 1000 microgram each during the first hour” NCT00397267 ↗ “Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)” NCT05755906 ↗ “Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.” NCT04848662 ↗ “intermittent budesonide inhalation suspension (1mg twice daily)” NCT04527016 ↗ “Budesonide Inhalation Aerosol administered as 2 inhalations BID” NCT02105012 ↗ “budesonide/formoterol (BD/FOR, branded) 200/6 mcg or 400/12 mcg” PMID 27334739 ↗ Jun 2016 “Budesonide/albuterol pressurized inhalation suspension, HFO” NCT06502366 ↗ “Budesonide (Nefecon®), 16mg/d for 36 weeks, taken orally.” NCT07030894 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF)” NCT06075095 ↗ “inhaled glucocorticoid [320 μg or 160 μg of budesonide]” PMID 32579807 ↗ Jun 2020 “320 µg budesonide / 9 µg formoterol fumarate dihydrate” NCT01329276 ↗ “budesonide/albuterol metered -dose inhaler (BDA MDI)” NCT06307665 ↗ “budesonide/formoterol/glycopyrronium 160/7.2/4.8 mcg” NCT07329946 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate” NCT05573464 ↗ “Budesonide, Glycopyrronium, and Formoterol Fumarate” NCT02536508 ↗ “Budesonide, Glycopyrronium and Formoterol Fumarate.” NCT03906045 ↗ “CHF 5188: fixed combination budesonide/carmoterol” NCT01070524 ↗ “Symbicort = budesonide plus formoterol fumarate” NCT00867737 ↗ “Budesonide 9mg/day for mild disease” NCT04921033 ↗ “combination budesonide/formoterol” NCT04331054 ↗ “inhaled budesonide for 7 days” NCT01526707 ↗ “Budesonide(inhaler)” NCT02790047 ↗ “budesonide” NCT03141424 ↗ “Budesonide” NCT00584636 ↗ |
| Known as | AQ001S | “AQ001S 0.125 mg/2 ml (budesonide 0.125 mg/2 ml inhalation solution) single-dose administered by nebulization.” NCT05148312 ↗ |
| Known as | BD MDI | “Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)” NCT02196077 ↗1“Budesonide BD MDI (PT008)” NCT03847896 ↗ |
| Known as | BIS | “budesonide inhalation suspension (BIS) 0.5 QD” NCT02187445 ↗ |
| Known as | BOS | “In this double-blind, placebo-controlled, phase 3 trial, patients 11-55 years of age with EoE and dysphagia were randomized 2:1 to receive budesonide oral suspension (BOS) 2.0...” PMID 33887475 ↗ Apr 20214“The pharmacokinetic (PK) profile of budesonide oral suspension (BOS) was evaluated during a phase 2, randomized, double-blind, placebo-controlled, dose-ranging study in...” PMID 35666852 ↗ Jun 2022 “Budesonide oral suspension (BOS) 2.0 mg twice daily (b.i.d.) was evaluated in two consecutive phase III studies (12 and 36 weeks, respectively).” PMID 39735351 ↗ Dec 2024 “We investigated the long-term safety and efficacy of budesonide oral suspension (BOS) in eosinophilic esophagitis (EoE).” PMID 39954913 ↗ Feb 2025 “budesonide oral suspension (BOS/Eohilia) 2.0 mg twice daily (b.i.d.)” PMID 41711386 ↗ Feb 2026 |
| Known as | BOT | “Budesonide orodispersible tablets (BOT) have been shown to be safe and effective in phase III double-blind trials of induction and 48-week maintenance therapy of eosinophilic...” PMID 39694205 ↗ Dec 20241“a budesonide orodispersible tablet (BOT)” PMID 32721437 ↗ Jul 2020 |
| Known as | BUD | “The participants were then randomized to budesonide/formoterol (Bud + Form; 400/12 μg BID), fluticasone/salmeterol (Flu + Salm; 250/50 μg BID), or formoterol only (12 μg BID)...” PMID 34464242 ↗ Nov 20219“Many studies have shown the superior efficacy of budesonide (BUD)/formoterol (FORM) maintenance and reliever therapy, but still lack evidence of its efficacy in Chinese asthma patients” PMID 22932169 ↗ Sep 2012 “To assess equivalence of twice daily (bid) budesonide/formoterol (BUD/FM) 160/4.5 μg via breath-actuated metered-dose inhaler (BAI) versus pressurized metered-dose inhaler (pMDI).” PMID 25596138 ↗ Jan 2015 “twice-daily inhaled corticosteroid/long-acting β2-agonist therapy [budesonide/formoterol (BUD/FOR)] 400 µg/12 µg in patients with symptomatic COPD at risk of exacerbations” PMID 29313286 ↗ Jan 2018 “Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).” NCT01351792 ↗ “Symbicort® total dose 400ug/12ug: is a combination of FORM (6ug) and ICS (Budesonide, (BUD) 200ug)” NCT01787097 ↗ “non-extrafine budesonide/formoterol (BUD/FF) 160/4.5 µg via dry-powder inhaler” PMID 33757520 ↗ Mar 2021 “fluticasone propionate/salmeterol [FP/S] and budesonide/formoterol [BUD/F]” PMID 30053956 ↗ Jun 2018 “Budesonide (BUD) DPI 200 mcg” NCT00442117 ↗ “Budesonide (BUD) Turbuhaler” NCT02991859 ↗ |
| Known as | Budecort | “Fluoxétine (Fluoxétine Arrow® 40 mg ) / Budésonide (Budecort® 2*400 mcg)” NCT04920838 ↗ |
| Known as | budedonide | “formoterol + budedonide (12/400 mcg) twice a day per 12 weeks” NCT01202084 ↗ |
| Known as | Budenofalk | “Budesonide (Budenofalk®), Prednisolone (Deltacortril®), Azathioprine (Imuran®)” NCT04921033 ↗2“received budesonide (Budenofalk, 9 mg/day initially, tapered to 4.5 mg/day)” PMID 25425655 ↗ Nov 2014 “9 mg budesonide once daily, Budenofalk, n = 30” PMID 24440672 ↗ Jan 2014 |
| Known as | Budenofalk granules | “budesonide 9 mg once daily (Budenofalk granules)” PMID 30195447 ↗ Sep 2018 |
| Known as | budesonide (Pulmicort) | “budesonide (Pulmicort)” NCT00462592 ↗ |
| Known as | Budesonide CFC | “Drug: Budesonide CFC” NCT00667992 ↗ |
| Known as | Budesonide Chlorofluorocarbon (CFC) | “Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks” NCT00667992 ↗ |
| Known as | Budesonide controlled ileal release (CR) capsules | “Drug: Budesonide controlled ileal release (CR) capsules” NCT05915104 ↗ |
| Known as | Budesonide Foam | “Drug: Budesonide Foam” NCT01349673 ↗ |
| Known as | Budesonide HFA | “Drug: Budesonide HFA” NCT00667992 ↗ |
| Known as | Budesonide Hydrofluoroalkane (HFA) | “Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks” NCT00667992 ↗ |
| Known as | Budesonide MMX | “Budesonide MMX™ is a once-daily oral formulation of budesonide that extends budesonide release throughout the colon using multi-matrix system (MMX) technology.” PMID 22892337 ↗ Aug 20121“Drug: Budesonide MMX®” NCT05915104 ↗ |
| Known as | Budesonide Nasal Spray | “Budesonide Nasal Spray 128ug/d for 8 week” NCT02668861 ↗ |
| Known as | budesonide oral suspension | “In this double-blind, placebo-controlled, phase 3 trial, patients 11-55 years of age with EoE and dysphagia were randomized 2:1 to receive budesonide oral suspension (BOS) 2.0...” PMID 33887475 ↗ Apr 20211“Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension.” PMID 34182150 ↗ Jun 2021 |
| Known as | Budesonide Powder for Inhalation | “Budesonide Powder for Inhalation” NCT02002715 ↗ |
| Known as | BUS | “2 mg budesonide suppositories (2 mg BUS;” PMID 29702300 ↗ Apr 2018 |
| Known as | Cortiment | “Cortiment (Budesonide 9 mg prolonged release tablet)” NCT05519514 ↗ |
| Known as | Entocort | “Prednisone, Entocort” NCT00109473 ↗ |
| Known as | Entocort CR | “receive (open-label) oral budesonide (Entocort CR 9 mg/day 8 weeks, 6 mg/day 2 weeks, 3 mg/day 2 weeks)” PMID 32681228 ↗ Jul 2020 |
| Known as | Entocort EC | “Budesonide (Entocort EC, AstraZeneca, Wilmington, DE) is an FDA-approved oral topical corticosteroid” NCT01950507 ↗1“Budesonide 80 mcg (Entocort EC) only” NCT01712854 ↗ |
| Known as | Eohilia | “budesonide oral suspension (BOS/Eohilia) 2.0 mg twice daily (b.i.d.)” PMID 41711386 ↗ Feb 20261“budesonide oral suspension (Eohilia)” NCT07358234 ↗ |
| Known as | MAP0010 | “0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks” NCT00697697 ↗4“2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents” NCT00697801 ↗ |
| Known as | MB-9 | “Oral Budesonide Suspension (MB-9)” NCT01642212 ↗ |
| Known as | miflonide | “combined LABD and inhaled steroids "miflonide" according to GOLD recommendations” NCT02257463 ↗ |
| Known as | Nefecon | “Budesonide (Nefecon®), 16mg/d for 36 weeks, taken orally.” NCT07030894 ↗ |
| Known as | NEUMOTEX | “budesonide dry powder inhaler (DPI) 400 mcg twice daily (BID) (NEUMOTEX™ 400)” NCT02233803 ↗ |
| Known as | OBS | “This Phase II study is comparing oral budesonide (OBS) to placebo to demonstrate that OBS induces a histologic response and a symptom response using a Dysphagia Symptom...” NCT01642212 ↗2“We investigated the efficacy and safety of a new formulation of oral budesonide suspension (OBS), a corticosteroid, in a prospective, placebo-controlled, dose-ranging study.” PMID 24907502 ↗ Jun 2014 “Oral Budesonide Suspension (OBS)” NCT02736409 ↗ |
| Known as | Oral Budesonide Suspension (OBS) | “Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.” NCT02605837 ↗1“Oral Budesonide Suspension (OBS)” NCT02736409 ↗ |
| Known as | OVB | “Placebo-controlled studies have not been conducted to evaluate the safety and efficacy of oral viscous budesonide (OVB).” PMID 20457157 ↗ May 20102“oral viscous budesonide (OVB) slurry” PMID 30872104 ↗ Mar 2019 “Drug: Oral Viscous Budesonide (OVB)” NCT01846962 ↗ |
| Known as | PT008 | “Budesonide (BD; PT008) and formoterol fumarate (FF; PT005) in a metered-dose inhaler (MDI); (BFF MDI; PT009)” NCT02196077 ↗1“Budesonide BD MDI (PT008)” NCT03847896 ↗ |
| Known as | Pulmicort | “Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment” NCT02224157 ↗21“Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment” NCT02149199 ↗ “Reference drug 1 : Pulmicort pMDI (Budesonide) Strength: (Budesonide 200ug/puff) Mode of administration: Orally inhaled administration, single dose (4 puffs)” NCT02165046 ↗ “Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.” NCT01147510 ↗ “Budesonide (Pulmicort) is a corticosteroid which is the mainstay treatment for CRS patients.” NCT04267042 ↗ “Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily” NCT02771717 ↗ “Budesonide (Pulmicort®, AstraZeneca Pty Ltd., Australia; 0.5 mg or 1mL/kg/dose)” NCT00146497 ↗ “0.5 mg of budesonide (Pulmicort®, AstraZeneca, solution of 0.5 mg/2 ml)” NCT04016220 ↗ “Pulmicort® : Budesonide Powder for Inhalation (200μg)” NCT07267130 ↗ “or budesonide/Pulmicort, or fluticasone Flovent HFA” NCT06272370 ↗ “Pulmicort (budesonide) Turbuhaler” NCT00232674 ↗ “Budesonide Turbuhaler (Pulmicort)” NCT00244608 ↗ “Pulmicort (budesonide) Turbuhaler” NCT00228475 ↗ “Pulmicort (budesonide) Respules” NCT00232648 ↗ “Pulmicort (budesonide) pMDI” NCT00234390 ↗ “budesonide (Pulmicort)” NCT00421122 ↗ “budesonide (Pulmicort)” NCT00646529 ↗ |
| Known as | Pulmicort flexhaler | “Budesonide will be provided as Pulmicort flexhaler.” NCT02357277 ↗ |
| Known as | Pulmicort Respules | “Subjects randomized to receive a single dose of budesonide by nebulization (Pulmicort Respules) 1mg at Visit 2, and a single dose of budesonide/albuterol by metered-dose...” NCT04848662 ↗5“Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.” NCT04032834 ↗ “2 mL of 0.5 mg/ 2 mL budesonide (Pulmicort Respules, AstraZeneca Canada, Mis sissauga, ON, Canada) will be added to the irrigation bottles of the patients.” NCT06837051 ↗ “Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.” NCT03421730 ↗ “Pulmicort Respules® 1.0 mg/2 ml is a budesonide inhalation suspension administered by nebulization.” NCT05148312 ↗ “budesonide 0.5mg/2ml Pulmicort Respules budesonide inhalation suspension(BIS)” NCT05325489 ↗ |
| Known as | Pulmicort Turbuhaler | “Budesonide (Pulmicort® Turbuhaler®) 800ug inhaled twice daily (BID) will be taken in addition to usual care for 36 weeks.” NCT06860542 ↗3“Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler” NCT00855959 ↗ “budesonide (Pulmicort Turbuhaler; AstraZeneca, Lund, Sweden)” NCT00175747 ↗ |
| Known as | Pulmicourt Turbuhaler | “The patients with eosinophilic bronchitis received Pulmicourt Turbuhaler (Budesonide 100µg) 2puff Q12h for 4 weeks.” NCT02002715 ↗ |
| Known as | Pulmocort turbuhaler | “Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid)” NCT00728715 ↗ |
| Known as | Rhinocort | “Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)” NCT04002349 ↗ |
| Known as | Rhinocort (commercial name for budesonide) | “Rhinocort (commercial name for budesonide)” NCT06830109 ↗ |
| Known as | Rhinocort Aqua | “Nasal budesonide (Rhinocort Aqua, AstraZeneca) is generally well tolerated.” NCT00560586 ↗ |
| Known as | Rhinorcort Astra Zeneca AB | “budesonide (Rhinorcort Astra Zeneca AB)” NCT04077892 ↗ |
| Known as | targeted-release budesonide | “Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.” PMID 28363480 ↗ Mar 2017 |
| Known as | TARPEYO | “The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA...” NCT06712407 ↗ |
| Known as | TRF-budesonide | “a novel targeted-release formulation of budesonide (TRF-budesonide)” PMID 28363480 ↗ Mar 2017 |
| Known as | unit dose budesonide | “Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.” NCT00627679 ↗1“2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents” NCT00697801 ↗ |
| Known as | VR647 | “VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece” NCT04032834 ↗ |
| Known as | VR647 Inhalation Suspension | “VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System” NCT03421730 ↗ |
| Action | Inhibit | “The mechanism of action of budesonide is similar to other corticosteroids and includes a wide range of inhibitory activities against multiple cell types” NCT02696850 ↗ |
| Modality | Small molecule | “Budesonide, a corticosteroid with an extensive first-pass hepatic metabolism appeared promising for the treatment of PBC.” PMID 10655252 ↗ Feb 2000 |
| Route | Inhaled | “inhaled budesonide” NCT00000575 ↗ |